Physiologas Secures Funding from Hokuhoku Capital for Home Hemodialysis
Key facts
- Physiologas Secures Funding from Hokuhoku Capital for Home Hemodialysis
- Physiologas Technologies Co., Ltd. has completed a Series A fourth close funding round by the end of May 2026, with Hokuhoku Capital Co., Ltd. and individual investors as new subscribers. The funds will be used for the design, development, prototyping, and non-clinical testing of home hemodialysis devices and consumables.
- Source: PR Times
- Date: June 9, 2026
Direct answer
Physiologas Technologies Co., Ltd. has completed a Series A fourth close funding round by the end of May 2026, with Hokuhoku Capital Co., Ltd. and individual investors as new subscribers. The funds will be used for the design, development, prototyping, and non-clinical testing of home hemodialysis devices and consumables.
- Citation
- Physiologas Secures Funding from Hokuhoku Capital for Home Hemodialysis (June 9, 2026), PR Times
- Source
- PR Times
- Date
- June 9, 2026
Physiologas Technologies Co., Ltd. has completed a Series A fourth close funding round by the end of May 2026, with Hokuhoku Capital Co., Ltd. and individual investors as new subscribers. The funds will be used for the design, development, prototyping, and non-clinical testing of home hemodialysis devices and consumables.
📋 Article Processing Timeline
- 📰 Published: June 9, 2026 at 10:00
- 🔍 Collected: June 9, 2026 at 10:36 (36 min after Published)
- 🤖 AI Analyzed: June 9, 2026 at 18:32 (7h 56m after Collected)
Physiologas Technologies Co., Ltd. (Headquarters: Sagamihara City, Kanagawa Prefecture; Representative Director: Kazuyoshi Miyawaki; hereinafter 'the Company') announces that it has completed a Series A fourth close funding round by the end of May 2026.
In this round, the Company conducted a third-party allotment of shares with Hokuhoku Capital Co., Ltd. and individual investors as new subscribers.
The funds raised will be used for the design, development, prototyping, and non-clinical testing (electrical safety testing, electromagnetic compatibility testing, biological safety testing, etc.) of home hemodialysis devices and consumables.
Please refer to the press release by Hokuhoku Capital Co., Ltd. for further details.
About Home Hemodialysis
Hemodialysis treatment in clinics is a standard therapy for 340,000 end-stage renal disease patients in Japan, typically requiring 4-hour sessions three times a week, imposing significant time constraints and physical burden. In contrast, home hemodialysis eliminates the need for hospital visits and allows for more frequent treatment, known to improve patient quality of life and prognosis.
However, in Japan, there are no dialysis devices specifically developed for home use. Patients must install large, complex clinic-grade machines that require plumbing for water supply and drainage, as well as complicated operations for water quality management and alarm responses. As a result, only about 800 patients currently undergo home hemodialysis, and the practice has not become widespread.
About the Company's Project
Based on the research results of Kenichi Kokubo (Associate Professor, School of Allied Health Sciences, Kitasato University, and Director/CTO of the Company), the Company is developing a compact, safe, home-specific hemodialysis device. This device utilizes a mechanism that recirculates dialysate within the system by adsorbing and removing uremic toxins.
The introduction of the Company's device is expected to enable frequent dialysis without hospital visits, leading to improved clinical prognosis. Furthermore, by enhancing the quality of life for patients and their families, it is anticipated to have a significant social impact by facilitating the social reintegration and employment of end-stage renal disease patients, offering high economic utility.
About Physiologas Technologies Co., Ltd.
Physiologas Technologies Co., Ltd. is a Kitasato University startup founded in 2020 with the purpose of 'Innovating healthcare through technology and delivering happier lives to patients and their families.'
Company Name: Physiologas Technologies Co., Ltd.
Location: 1-15-1 Kitasato, Minami-ku, Sagamihara City, Kanagawa Prefecture (within Kitasato University Sagamihara Campus)
Established: March 2020
Capital: 349,556,075 yen (as of May 29, 2026)
Business: Development, manufacture, and sale of medical devices (home hemodialysis devices)
URL: https://physiologas.co.jp/
Inquiries: Physiologas Technologies Co., Ltd. Public Relations
Contact: https://physiologas.co.jp/jp-contact.html
In this round, the Company conducted a third-party allotment of shares with Hokuhoku Capital Co., Ltd. and individual investors as new subscribers.
The funds raised will be used for the design, development, prototyping, and non-clinical testing (electrical safety testing, electromagnetic compatibility testing, biological safety testing, etc.) of home hemodialysis devices and consumables.
Please refer to the press release by Hokuhoku Capital Co., Ltd. for further details.
About Home Hemodialysis
Hemodialysis treatment in clinics is a standard therapy for 340,000 end-stage renal disease patients in Japan, typically requiring 4-hour sessions three times a week, imposing significant time constraints and physical burden. In contrast, home hemodialysis eliminates the need for hospital visits and allows for more frequent treatment, known to improve patient quality of life and prognosis.
However, in Japan, there are no dialysis devices specifically developed for home use. Patients must install large, complex clinic-grade machines that require plumbing for water supply and drainage, as well as complicated operations for water quality management and alarm responses. As a result, only about 800 patients currently undergo home hemodialysis, and the practice has not become widespread.
About the Company's Project
Based on the research results of Kenichi Kokubo (Associate Professor, School of Allied Health Sciences, Kitasato University, and Director/CTO of the Company), the Company is developing a compact, safe, home-specific hemodialysis device. This device utilizes a mechanism that recirculates dialysate within the system by adsorbing and removing uremic toxins.
The introduction of the Company's device is expected to enable frequent dialysis without hospital visits, leading to improved clinical prognosis. Furthermore, by enhancing the quality of life for patients and their families, it is anticipated to have a significant social impact by facilitating the social reintegration and employment of end-stage renal disease patients, offering high economic utility.
About Physiologas Technologies Co., Ltd.
Physiologas Technologies Co., Ltd. is a Kitasato University startup founded in 2020 with the purpose of 'Innovating healthcare through technology and delivering happier lives to patients and their families.'
Company Name: Physiologas Technologies Co., Ltd.
Location: 1-15-1 Kitasato, Minami-ku, Sagamihara City, Kanagawa Prefecture (within Kitasato University Sagamihara Campus)
Established: March 2020
Capital: 349,556,075 yen (as of May 29, 2026)
Business: Development, manufacture, and sale of medical devices (home hemodialysis devices)
URL: https://physiologas.co.jp/
Inquiries: Physiologas Technologies Co., Ltd. Public Relations
Contact: https://physiologas.co.jp/jp-contact.html
FAQ
Where is Physiologas Technologies headquartered?
At 1-15-1 Kitasato, Minami-ku, Sagamihara City, Kanagawa Prefecture, within Kitasato University Sagamihara Campus.
Who is the CEO of Physiologas Technologies?
Kazuyoshi Miyawaki serves as the Representative Director.
Who were the subscribers in this funding round?
Hokuhoku Capital Co., Ltd. and individual investors.